AbbVie (MEX:ABBV) Cyclically Adjusted Revenue per Share: MXN547.66 (As of Mar. 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
71 GF Score
Price MXN4,398.00
GF Value MXN3,601.76
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted Revenue per Share?

AbbVie MEX:ABBV 71 Cyclically Adjusted Revenue per Share is MXN547.66 as of Mar. 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 71/100 and a GF Value™ of MXN3,601.76 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AbbVie's adjusted revenue per share for the three months ended in Mar. 2026 was MXN152.495. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN547.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AbbVie's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AbbVie was 14.30% per year. The lowest was 8.90% per year. And the median was 11.20% per year.

As of today (2026-07-13), AbbVie's current stock price is MXN4398.00. AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN547.66. AbbVie's Cyclically Adjusted PS Ratio of today is 8.03.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.24. The lowest was 4.91. And the median was 6.35.


AbbVie  (MEX:ABBV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4398.00/547.66
=8.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.24. The lowest was 4.91. And the median was 6.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AbbVie Cyclically Adjusted Revenue per Share Related Terms


AbbVie Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted Revenue per Share Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 426.63 473.17 440.74 578.98 553.06

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 571.65 567.55 553.56 553.06 547.66

MEX:ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


MEX:ABBV
71GF Score
AbbVie Inc MEX:ABBV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=152.495/330.2130*330.2130
=152.495

Current CPI (Mar. 2026) = 330.2130.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 73.113 241.018 100.170
201609 75.833 241.428 103.721
201612 86.223 241.432 117.930
201703 76.796 243.801 104.015
201706 78.450 244.955 105.755
201709 79.192 246.819 105.949
201712 94.639 246.524 126.767
201803 90.314 249.554 119.505
201806 103.472 251.989 135.592
201809 101.686 252.439 133.014
201812 108.640 251.233 142.793
201903 102.392 254.202 133.009
201906 106.853 256.143 137.752
201909 112.874 256.759 145.165
201912 110.395 256.974 141.858
202003 136.185 258.115 174.225
202006 146.103 257.797 187.144
202009 160.664 260.280 203.832
202012 154.780 260.474 196.221
202103 149.824 264.877 186.780
202106 156.457 271.696 190.154
202109 165.954 274.310 199.775
202112 171.557 278.802 203.192
202203 151.606 287.504 174.127
202206 165.192 296.311 184.092
202209 167.761 296.808 186.642
202212 165.524 296.797 184.160
202303 124.074 301.836 135.739
202306 134.218 305.109 145.261
202309 136.981 307.789 146.961
202312 136.683 306.746 147.140
202403 115.228 312.332 121.825
202406 149.602 314.175 157.239
202409 160.678 315.301 168.277
202412 177.344 315.605 185.552
202503 154.048 319.799 159.064
202506 163.977 322.561 167.867
202509 163.317 324.800 166.039
202512 168.479 324.054 171.681
202603 152.495 330.213 152.495

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN547.66 mean?
AbbVie (MEX:ABBV) has a Cyclically Adjusted Revenue per Share of MXN547.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's Cyclically Adjusted Revenue per Share too high?
AbbVie's current Cyclically Adjusted Revenue per Share is MXN547.66. Overall, AbbVie has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cyclically Adjusted Revenue per Share compare to MRK and JNJ?
AbbVie's Cyclically Adjusted Revenue per Share of MXN547.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current Cyclically Adjusted Revenue per Share is MXN547.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,601.76, compared to a current price of MXN4,398.00 — trading 22.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN547.66. AbbVie's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Cyclically Adjusted Revenue per Share is MXN547.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,398.00 is trading 22.1% above its estimated GF Value™ of MXN3,601.76. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Cyclically Adjusted Revenue per Share: MXN547.66
  • GF Value™: MXN3,601.76 vs. price of MXN4,398.00 (22.1% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
71GF Score

Get the complete analysis for MEX:ABBV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,398.00
Price
MXN3,601.76
GF Value